No connection

Search Results

ABBV vs HIMS

ABBV
AbbVie Inc.
NEUTRAL
Price
$219.26
Market Cap
$387.52B
Sector
Healthcare
AI Confidence
68%
HIMS
Hims & Hers Health, Inc.
NEUTRAL
Price
$29.39
Market Cap
$6.7B
Sector
Healthcare
AI Confidence
85%

Valuation

P/E Ratio
ABBV
163.63
HIMS
57.63
Forward P/E
ABBV
15.42
HIMS
21.31
P/B Ratio
ABBV
-146.66
HIMS
12.35
P/S Ratio
ABBV
6.5
HIMS
2.85
EV/EBITDA
ABBV
15.27
HIMS
41.23

Profitability

Gross Margin
ABBV
71.46%
HIMS
73.83%
Operating Margin
ABBV
35.5%
HIMS
2.72%
Profit Margin
ABBV
4.0%
HIMS
5.47%
ROE
ABBV
137.96%
HIMS
25.23%
ROA
ABBV
9.59%
HIMS
5.29%

Growth

Revenue Growth
ABBV
9.1%
HIMS
28.4%
Earnings Growth
ABBV
-88.7%
HIMS
-17.4%

Financial Health

Debt/Equity
ABBV
--
HIMS
2.07
Current Ratio
ABBV
0.72
HIMS
1.9
Quick Ratio
ABBV
0.47
HIMS
1.51

Dividends

Dividend Yield
ABBV
3.05%
HIMS
--
Payout Ratio
ABBV
490.15%
HIMS
0.0%

AI Verdict

ABBV NEUTRAL

The Advanced Deterministic Scorecard reveals a mixed health profile with a Piotroski F-Score of 4/9 indicating stable but not strong fundamentals, while the absence of an Altman Z-Score prevents a clear distress risk assessment. Despite robust operating margins and consistent revenue growth, the company faces significant headwinds from negative earnings growth, an extremely high P/E ratio, and a dangerously elevated payout ratio. Strong historical price performance and analyst buy sentiment are counterbalanced by bearish insider activity and deteriorating profitability trends. The stock appears to trade at a substantial premium to its intrinsic value, suggesting limited margin of safety.

Strengths
High operating margin (35.50%) indicating strong pricing power and cost control
Consistent revenue growth (9.10% YoY) outpacing sector average
Strong track record of earnings surprises (22 out of 25 quarters beat estimates)
Risks
Extremely high P/E ratio (163.63) vs forward P/E (15.42), suggesting potential overvaluation on trailing basis
Earnings growth collapsing (YoY: -88.70%, Q/Q: -88.10%) indicating severe profitability deterioration
Unsustainable dividend payout ratio (490.15%) threatening dividend security
HIMS NEUTRAL

HIMS demonstrates strong operational health with a Piotroski F-Score of 7/9, signaling robust financial trends and efficiency. However, the stock is severely overvalued from a deterministic standpoint, trading at $29.39 against a Graham Number of $5.23 and an Intrinsic Value of $3.57. While revenue growth is strong (28.4%) and gross margins are impressive (73.83%), the valuation premium is extreme. This, combined with bearish insider selling and a negative technical trend, offsets the company's fundamental operational strengths.

Strengths
Strong Piotroski F-Score (7/9) indicating high financial health
Excellent Gross Margins (73.83%) providing significant pricing power
Consistent Revenue Growth (28.4% YoY and Q/Q)
Risks
Extreme valuation gap between current price and deterministic fair value
Bearish insider activity, specifically consistent selling by the CFO
Negative Year-over-Year earnings growth (-17.40%)

Compare Another Pair

ABBV vs HIMS: Head-to-Head Comparison

This page compares AbbVie Inc. (ABBV) and Hims & Hers Health, Inc. (HIMS) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.

Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.

Home
Terminal
AI Chat
Markets
Profile